TREACE MEDICAL CONCEPTS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $212.7M | $209.4M | $187.1M | $141.8M | $94.4M |
| Cost of revenue | $42.9M | $41.1M | $35.2M | $25.5M | $16.9M |
| Gross profit | $169.8M | $168.3M | $151.9M | $116.3M | $77.5M |
| Research and development | $20.3M | $20.6M | $15.4M | $13.6M | $10.2M |
| Operating expenses | $223.9M | $224.0M | $203.4M | $151.2M | $94.0M |
| Operating income | -$54.2M | -$55.7M | -$51.4M | -$34.8M | -$16.5M |
| Interest expense | $5.3M | $5.3M | $5.2M | $4.4M | $4.1M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.0M | -$55.7M | -$49.5M | -$42.8M | -$20.6M |
| Balance Sheet | |||||
| Cash and equivalents | $10.7M | $11.3M | $13.0M | $19.5M | $105.8M |
| Current assets | $132.1M | $161.4M | $198.4M | $133.4M | $138.0M |
| Total assets | $190.6M | $217.1M | $251.9M | $159.0M | $140.8M |
| Current liabilities | $30.6M | $34.9M | $45.0M | $30.2M | $18.2M |
| Total liabilities | $103.2M | $104.2M | $114.0M | $98.5M | $47.7M |
| Total debt | $60.0M | $54.0M | $54.0M | $54.0M | $30.0M |
| Stockholders' equity | $87.3M | $112.9M | $137.9M | $60.5M | $93.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$16.0M | -$37.2M | -$34.6M | -$30.6M | -$17.2M |
| Depreciation and amortization | $10.6M | $8.4M | $5.4M | $2.1M | $685,000 |
| Stock-based compensation | $33.8M | $30.6M | $17.4M | $8.1M | $3.4M |
| Capital expenditure | $13.5M | $11.6M | $11.5M | $14.8M | $2.7M |
| Free cash flow | -$29.5M | -$48.8M | -$46.0M | -$45.5M | -$19.9M |
| Impairments | $0 | $0 | $0 | $300,000 | $0 |
Shares outstanding 64.9M · Free float 53.7%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.